ne3107
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Aug 5, 2021 (NCT04669028)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06847191 | Phase 2 | Feb 28, 2025 | BioVie Inc. |
| NCT06757010 | Phase 2 | Feb 28, 2025 | BioVie Inc. |
| NCT05970575 | Phase 2 | Aug 21, 2023 | BioVie Inc., Neurological Associates of West Los Angeles |
| NCT05227820 | Phase 2 | Jan 19, 2022 | BioVie Inc., Neurological Associates of West Los Angeles |
| NCT05083260 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | BioVie Inc. |
| NCT04669028 | Phase 3 | Aug 5, 2021 | BioVie Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioVie Inc. | For profit | 6 | 4 | 2 | 2021 |
| Neurological Associates of West Los Angeles | Academic/Hospital | 2 | 2 | 1 | 2022 |
2 organizations
Page 1 / 1